Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia
Year: 2015
Type: article
Abstract: peripheral blood g-globin to b-globin messenger RNA was 0.89 (range, 0.34-1.4).Vorinostat was well tolerated at the doses tested.Vorinostat toxicity (fatigue, abdominal pain) was mild to moderate, with the exception of pain, indistinguishable from sickle pain in 3 patients and headaches in 1 patient.With intermittent dosing, we were able to prevent thrombocytopenia, a common effect of vorinostat use in malignancy.However, it is unclear whether sufficient doses were used in this study because neither thrombocytopenia nor a convincing induction of HbF was produced.We have demonstrated the safety and tolerability of an oral pan-HDAC inhibitor, vorinostat, in 5 patients with SCD, with minimal adverse events.Future studies with vorinostat should employ higher cumulative weekly doses, probably marked by induction of relative thrombocytopenia.Potentially more promising is the potential of using HDAC1 and HDAC2 selective agents that would mediate HbF induction 6 (with tolerability that allows more robust dosing) and using combinations of HDAC inhibitors with hydroxyurea.
Source: Blood
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W775930075